OncoSec Medical Inc. (NASDAQ:ONCS

OncoSec Medical Inc. (NASDAQ:ONCS) Hits Record Highs after Trial Results

OncoSec Medical Inc. (NASDAQ:ONCS)

Shares of OncoSec Medical Inc. (NASDAQ:ONCS) hit a new record high after the company reported positive follow-up data from its Phase 2 OMS 1-102 combination study of ImmunoPulse IL-12 and Keytruda. The stock was up by 60% in Monday’s trading session to end the day at $2 a share.

OncoSec Medical Inc. (NASDAQ:ONCS

ONCS Stock Performance

OncoSec Medical Inc. (NASDAQ:ONCS) is currently trading in an uptrend, after being in consolidation for the better part of the year. For the full year, the stock is up by more than 60%. Following the rally, Maxim analyst Jason Kolbert has assigned a ‘Buy’ rating on the stock with a share price target of $5. The price target represents a 146% potential upside from current trading levels.

Renewed investor interest on the stock follows the announcement that a combination of ImmunoPulse il-12 and Keytruda demonstrated a 57% progression-free survival at 15 months.

Trial Results

According to OncoSec Medical Inc. (NASDAQ:ONCS), the new data demonstrates that a combination of the two therapies can prime a coordinated innate and adaptive immune response. The findings also suggest that the approach can reshape the tumor microenvironment yielding a robust anti-tumor response.

“The robust PFS benefit and tolerability observed with ImmunoPulse IL-12 plus pembrolizumab is the first demonstrating efficacy in a predicted PD-1 non-responder population and shows that the combination represents a potentially important addition to the treatment landscape for metastatic melanoma patients who have progressed or are progressing on anti-PD-1 therapy,” said CEO Dan O’Connor.

OncoSec Financial Results

Separately, OncoSec Medical Inc. (NASDAQ:ONCS) reported fourth-quarter financial results that indicated a significant improvement in operational efficiencies. For the three months ended July 31, 2017, the company generated a net loss of (-$5.8) million or (-$0.28) a share. The performance was an improvement from a net loss of (-$6.6) million reported last year.

OncoSec Medical Inc. (NASDAQ:ONCS) full-year net loss came in at (-$21.4) million or (-$1.06) a share, compared to a net loss of (-$26.9) million reported last year. The company attributes the decrease in net loss to a $2.2 million reduction in non-stock-based compensation. Research and development expenses also dropped from $14.7 million as of last year to $$12 million.

OncoSec Medical Inc. (NASDAQ:ONCS) exited the FY2017 with a total of $11.4 million in cash and cash equivalent compared to $28.7 million as of July 31, 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NASDAQ:ONCS

Is OncoSec Medical Inc. (NASDAQ:ONCS) A Buy?

OncoSec Medical Inc. (NASDAQ:ONCS)

Shares of OncoSec Medical Inc. (NASDAQ:ONCS) traded lower following the posting of better than expected fourth quarter and full year financial results. The stock was down by 3.79% in Monday’s trading session, to end the day at $1.27 a share.

OncoSec Medical Inc. (NASDAQ:ONCS)

ONCS Stock Performance

OncoSec Medical Inc. (NASDAQ:ONCS) has gained more than 30% in market value over the past month. The impressive run has seen the stock trade above January’s trading levels after erasing a good chunk of losses accrued for the better part of the year. The stock faces immediate resistance at the $1.30 mark, above which it could make a push for the $1.52 mark.

Renewed investor interest in the stock follows the announcement that the company has made significant progress in the development of its lead clinical program ImmunoPulse IL-12. The company is developing the program for the treatment of metastatic melanoma.

During the fourth quarter, the biotechnology company presented positive Phase 2 data of ImmunoPulse IL-12, in combination with pembrolizumab.

“Our organization remains focused on advancing our PISCES/KEYNOTE-695 registration-directed trial to address this significant unmet medical need through an innovative accelerated pathway,” said CEO, Punit Dhillon.

OncoSec Q4 Financial Results

In addition to progress on the clinical development front, OncoSec Medical Inc. (NASDAQ:ONCS) is also working on trimming its net loss as it eyes positive cash flow. For the three months ended July 31, 2017, the company generated a net loss of (-$5.8) million, down from (-$6.6) million reported last year. Net loss for the full year dropped to ($21.4) million from ($26.9) million.

OncoSec Medical Inc. (NASDAQ:ONCS) attributes the decrease in net loss to a $2.2 million decrease in non-cash, stock-based compensation expense and a $1.8 million decrease in Research and Development Expense. The company did not generate any revenue in the fourth quarter and full year.

The biotechnology company exited the fourth quarter with $11.4 million in cash and cash equivalent, down from $28.7 million as of July 31, 2016. The funds should finance the company’s operations through the third quarter of FY2018.

Last Month OncoSec Medical Inc. (NASDAQ:ONCS) closed a $7.1 million direct offering of 5.3 million shares of common stock, priced at $1.34 a share. The company also issued warrants for the purchase of additional shares at an exercise price of $1.25 a share.

OncoSec intends to use net proceeds of about $6.2 million for working capital and general corporate purposes such as the PISCES/KEYNOTE-695 study, among other clinical, research and development activities.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OncoSec Medical Inc. (NASDAQ:ONCS) Falls After Pricing Offering

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares fell 12.9% after the biotechnology company announced it has entered into a definitive purchase agreement with accredited investors. Pursuant to the agreement, the company is to issue 5.3 million shares of common stock at $1.34 a share.

OncoSec Medical Inc. (NASDAQ:ONCS)

Public Offering

The company has also agreed to issue the investors unregistered warrants, expiring in 5.5 years, for the purchase of up to 3.9 million shares of common stock at $1.25 a share. OncoSec Medical expects gross proceeds of $7.1 million from the offering.

OncoSec Medical Inc. (NASDAQ:ONCS) expects net proceeds of approximately $6.2 million after the deduction of fees and other expenses. The offering should close on or about October 25, 2017.

Net proceeds from the offering are to be used for working capital, general corporate purposes, and for ongoing clinical research and development programs. The pricing of the purchase agreement appears to have spooked investors as seen by the stock’s failure to rise above $1.30.

Prior to the announcement of the offering, OncoSec Medical Inc. (NASDAQ:ONCS) had been on an impressive run after a string of positive clinical trial results. However, the uptrend appears to be losing momentum – threatening to push the stock to multi-year lows.

Clinical Trials

OncoSec has been trading higher in the market following the presentation of positive Phase 2 data for it lead candidate drug ImmunoPulse IL-12 for the treatment of metastatic melanoma. Phase 2 study results indicate that only 10% of the patients treated with the drug in combination with pembrolizumab experienced serious adverse events

Preliminary trial results also indicate that ImmunoPulse IL-12 has the potential to trigger key immunologic events.

“Collectively, these study findings reinforce the combination of ImmunoPulse IL-12 and pembrolizumab to address a significant unmet medical need in melanoma patients who are unlikely to respond to anti-PD-1 therapies,” said Punit Dhillon, CEO, and President of OncoSec.

OncoSec Medical Inc. (NASDAQ:ONCS) is to present additional data in ongoing Phase 2 combination study at the upcoming Society for Immunotherapy of Cancer Annual Meeting.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) To Make Key Presentations

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares gained 10.1% after the company said it will present updated clinical data on the study of ImmunoPulse IL-12, its lead oncology program. The biotechnology company will make the presentation at the upcoming 9th World Congress of Melanoma.

OncoSec Medical Inc. (NASDAQ:ONCS)

ImmunoPulse IL-12 Presentations

In addition, OncoSec Medical Inc. (NASDAQ:ONCS) is to present updated clinical data from its Phase 2 Investigator Sponsored trial in patients with unresectable metastatic melanoma. The presentation will occur at the upcoming Society for Immunotherapy of Cancer (“SITC”) 32nd Annual Meeting to be held on November 8-12, 2017,

ImmunoPulse IL-12 is a nonviral gene delivery platform designed to utilize the power of the human immune system to target and attack tumors in the body. It is currently in Phase 2 clinical monotherapy trial, for the treatment of stage three and four melanoma.

A presentation by Dr. Alain Algazi will contrast the candidate drug to its combination with pembrolizumab. The presentation will also include clinical and biomarker data from a recently completed Phase 3 monotherapy trial.

“These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration-directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018,” said CEO Punit Dhillon.

 ONCS Stock Performance

Investor confidence on OncoSec Medical Inc. (NASDAQ:ONCS) is slowly building following a string of positive news on the development of the company’s lead oncology program. The stock has bounced back from multi-year lows of below $1 a share and bullish momentum continues to grow in strength.

However, the stock is still down by more than 5% for the year after coming under pressure after rising to $1.50 share. OncoSec Medical Incorporated faces immediate resistance at $1.25 a close above which could see the stock making a push for the $1.50 mark.

OncoSec Medical Inc. (NASDAQ:ONCS) has elicited significant investor interest in the recent past as most of them take note of its robust and differentiated approach in developing cancer treatments. The company is currently merging over two decades of research and development processes to accelerate the development of its lead candidate product.

The company’s flagship product, ImmunoPulse IL-12 has already shown to deliver equal gene transmission rates while maintaining a high safety profile. OncoSec Medical Inc. (NASDAQ:ONCS) is advancing the treatment into Phase 2 trials with projected milestone for treatment approval set for 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.